SG11201603091QA - Ferric citrate for reducing cardiac failure in chronic kidney disease patients - Google Patents
Ferric citrate for reducing cardiac failure in chronic kidney disease patientsInfo
- Publication number
- SG11201603091QA SG11201603091QA SG11201603091QA SG11201603091QA SG11201603091QA SG 11201603091Q A SG11201603091Q A SG 11201603091QA SG 11201603091Q A SG11201603091Q A SG 11201603091QA SG 11201603091Q A SG11201603091Q A SG 11201603091QA SG 11201603091Q A SG11201603091Q A SG 11201603091QA
- Authority
- SG
- Singapore
- Prior art keywords
- kidney disease
- chronic kidney
- disease patients
- ferric citrate
- cardiac failure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899866P | 2013-11-04 | 2013-11-04 | |
| PCT/US2014/063643 WO2015066593A1 (en) | 2013-11-04 | 2014-11-03 | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201603091QA true SG11201603091QA (en) | 2016-05-30 |
Family
ID=53005244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201603091QA SG11201603091QA (en) | 2013-11-04 | 2014-11-03 | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20160256486A1 (en) |
| EP (2) | EP3065734A4 (en) |
| JP (3) | JP2016535780A (en) |
| KR (1) | KR102392441B1 (en) |
| CN (1) | CN105873583A (en) |
| AU (1) | AU2014341975A1 (en) |
| BR (1) | BR112016009901A8 (en) |
| CA (1) | CA2928200A1 (en) |
| EA (1) | EA201690926A1 (en) |
| HK (1) | HK1223031A1 (en) |
| IL (1) | IL245317A0 (en) |
| MX (1) | MX2016005734A (en) |
| SG (1) | SG11201603091QA (en) |
| TW (2) | TW202203910A (en) |
| WO (1) | WO2015066593A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2456426A1 (en) | 2009-07-21 | 2012-05-30 | Keryx Biopharmaceuticals, Inc. | Ferric citrate dosage forms |
| CA2912911C (en) | 2013-06-05 | 2023-10-03 | Tricida, Inc. | Proton-binding polymers for oral administration |
| US10172882B2 (en) | 2014-06-22 | 2019-01-08 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| EP3229816B1 (en) | 2014-12-10 | 2020-02-05 | Tricida Inc. | Proton-binding polymers for oral administration |
| US20200054669A1 (en) | 2016-05-06 | 2020-02-20 | Tricida, Inc. | Compositions for and methods of treating acid-base disorders |
| AU2018360867A1 (en) | 2017-11-03 | 2020-04-30 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| AU2019370677A1 (en) * | 2018-10-29 | 2021-05-27 | Pharmacosmos Holding A/S | Treating iron deficiency with ferric carboxymaltose |
| CN114286682A (en) * | 2019-02-09 | 2022-04-05 | 法码科思莫斯控股有限公司 | Iron deficiency for treating individuals at risk of cardiovascular adverse events and iron for treating atrial fibrillation |
| EP4347022A1 (en) * | 2021-05-27 | 2024-04-10 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE351366B (en) * | 1965-06-08 | 1972-11-27 | Teikoku Hormone Mfg Co Ltd | |
| US20050203169A1 (en) * | 2001-08-06 | 2005-09-15 | Moskowitz David W. | Methods and compositions for treating diseases associated with excesses in ACE |
| WO2007022435A2 (en) * | 2005-08-18 | 2007-02-22 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| CA2640763C (en) * | 2006-01-30 | 2016-10-11 | Globoasia, Llc | Method of reversing, preventing, delaying or stabilizing soft tissue calcification |
| KR20080094013A (en) * | 2006-01-30 | 2008-10-22 | 글로보아시아 엘엘씨 | Method of reversing, preventing, delaying or stabilizing soft tissue calcification |
| EP2456426A1 (en) * | 2009-07-21 | 2012-05-30 | Keryx Biopharmaceuticals, Inc. | Ferric citrate dosage forms |
| WO2012006473A1 (en) * | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP2015535209A (en) * | 2012-06-21 | 2015-12-10 | ケリク バイオファーマシューティカルス， インコーポレーテッド | Use of ferric citrate in the treatment of patients with chronic kidney disease |
-
2014
- 2014-11-03 EA EA201690926A patent/EA201690926A1/en unknown
- 2014-11-03 EP EP14858106.9A patent/EP3065734A4/en not_active Ceased
- 2014-11-03 BR BR112016009901A patent/BR112016009901A8/en not_active Application Discontinuation
- 2014-11-03 AU AU2014341975A patent/AU2014341975A1/en not_active Abandoned
- 2014-11-03 CA CA2928200A patent/CA2928200A1/en not_active Abandoned
- 2014-11-03 EP EP20173867.1A patent/EP3747432A1/en active Pending
- 2014-11-03 WO PCT/US2014/063643 patent/WO2015066593A1/en active Application Filing
- 2014-11-03 US US15/031,678 patent/US20160256486A1/en not_active Abandoned
- 2014-11-03 JP JP2016552432A patent/JP2016535780A/en active Pending
- 2014-11-03 KR KR1020167014000A patent/KR102392441B1/en active IP Right Grant
- 2014-11-03 SG SG11201603091QA patent/SG11201603091QA/en unknown
- 2014-11-03 CN CN201480072217.1A patent/CN105873583A/en active Pending
- 2014-11-04 TW TW110136784A patent/TW202203910A/en unknown
- 2014-11-04 TW TW103138244A patent/TWI744215B/en active
-
2015
- 2015-01-29 MX MX2016005734A patent/MX2016005734A/en unknown
-
2016
- 2016-04-27 IL IL245317A patent/IL245317A0/en unknown
- 2016-09-27 HK HK16111332.6A patent/HK1223031A1/en unknown
-
2018
- 2018-12-11 US US16/216,772 patent/US20190307791A1/en not_active Abandoned
-
2019
- 2019-07-31 JP JP2019140640A patent/JP6828100B2/en active Active
-
2021
- 2021-01-20 JP JP2021007091A patent/JP2021073230A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201609088A (en) | 2016-03-16 |
| US20160256486A1 (en) | 2016-09-08 |
| MX2016005734A (en) | 2016-11-08 |
| JP2019206562A (en) | 2019-12-05 |
| BR112016009901A8 (en) | 2020-04-14 |
| EP3065734A1 (en) | 2016-09-14 |
| JP6828100B2 (en) | 2021-02-10 |
| HK1223031A1 (en) | 2017-07-21 |
| JP2016535780A (en) | 2016-11-17 |
| JP2021073230A (en) | 2021-05-13 |
| KR102392441B1 (en) | 2022-05-02 |
| EA201690926A1 (en) | 2016-09-30 |
| EP3747432A1 (en) | 2020-12-09 |
| EP3065734A4 (en) | 2017-05-17 |
| KR20160096597A (en) | 2016-08-16 |
| IL245317A0 (en) | 2016-06-30 |
| TW202203910A (en) | 2022-02-01 |
| AU2014341975A1 (en) | 2016-05-19 |
| US20190307791A1 (en) | 2019-10-10 |
| TWI744215B (en) | 2021-11-01 |
| CA2928200A1 (en) | 2015-05-07 |
| WO2015066593A1 (en) | 2015-05-07 |
| CN105873583A (en) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223031A1 (en) | Ferric citrate for reducing cardiac failure in chronic kidney disease patients | |
| HK1214503A1 (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| IL285843A (en) | Ibrutinib for use in the treatment of chronic graft versus host disease | |
| HK1218402A1 (en) | System and method for performing alternative and sequential blood and peritoneal dialysis modalities | |
| IL242804B (en) | Pridopidine for use in reducing impairment of functional capacity in huntington disease patients | |
| EP3862044C0 (en) | Dual-tip hemodialysis catheter | |
| EP2950874A4 (en) | Bodily lumen occlusion | |
| EP2925382A4 (en) | Extracorporeal ambulator assist lung | |
| EP2968048A4 (en) | Surgical patient side cart with steering interface | |
| EP2833957A4 (en) | Therapy for kidney disease and/or heart failure by intradermal infusion | |
| HK1214526A1 (en) | Therapeutic agent for eyeground disease | |
| HK1220898A1 (en) | Use of derivatives with c-o-p bonds in patients with renal failure c-o-p | |
| CL2016000447A1 (en) | Risk markers for cardiovascular disease in patients with chronic kidney disease. | |
| HK1225443A1 (en) | Marker for statin treatment stratification in heart failure | |
| IL240218B (en) | Catheter for denervation | |
| EP2959908A4 (en) | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease | |
| EP2959905A4 (en) | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease | |
| EP2959906A4 (en) | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease | |
| PL2875049T3 (en) | Methods for preventing and treating chronic kidney disease (ckd) | |
| GB201305758D0 (en) | Blood Pump | |
| GB201305761D0 (en) | Blood Pump | |
| HK1220622A1 (en) | Physiological ligands for gpr139 gpr139 | |
| EP3217987A4 (en) | Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | |
| EP2959907A4 (en) | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease | |
| PL3007772T3 (en) | Compositions for use in the treatment of dyslipidaemia in chronic kidney disease |